10.15
前日終値:
$10.59
開ける:
$10.605
24時間の取引高:
1.11M
Relative Volume:
0.32
時価総額:
$719.64M
収益:
-
当期純損益:
$-117.81M
株価収益率:
-5.3989
EPS:
-1.88
ネットキャッシュフロー:
$74.30M
1週間 パフォーマンス:
-6.45%
1か月 パフォーマンス:
+47.31%
6か月 パフォーマンス:
+185.92%
1年 パフォーマンス:
+19.55%
Omeros Corporation Stock (OMER) Company Profile
名前
Omeros Corporation
セクター
電話
206-676-5000
住所
201 ELLIOTT AVENUE WEST, SEATTLE, WA
OMER を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
OMER
Omeros Corporation
|
10.15 | 750.84M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-10 | 開始されました | H.C. Wainwright | Buy |
| 2024-12-23 | 開始されました | D. Boral Capital | Buy |
| 2024-11-14 | 開始されました | Rodman & Renshaw | Buy |
| 2022-12-08 | ダウングレード | UBS | Buy → Neutral |
| 2022-11-08 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-06-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-10-08 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-10-01 | ダウングレード | Maxim Group | Buy → Hold |
| 2021-10-01 | ダウングレード | Wedbush | Neutral → Underperform |
| 2021-09-27 | 開始されました | JP Morgan | Neutral |
| 2021-02-01 | 開始されました | UBS | Buy |
| 2020-10-20 | 開始されました | BofA Securities | Buy |
| 2020-08-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-14 | 繰り返されました | Maxim Group | Buy |
| 2019-05-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-07-12 | 開始されました | Seaport Global Securities | Buy |
| 2018-03-23 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-03-05 | ダウングレード | Needham | Buy → Hold |
| 2017-11-08 | 開始されました | H.C. Wainwright | Buy |
| 2017-05-11 | ダウングレード | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | 繰り返されました | Maxim Group | Buy |
| 2017-03-17 | 繰り返されました | Needham | Buy |
| 2016-11-16 | 繰り返されました | Wedbush | Outperform |
| 2016-11-10 | 繰り返されました | Needham | Buy |
| 2016-08-10 | 繰り返されました | Maxim Group | Buy |
| 2016-06-03 | 開始されました | Cantor Fitzgerald | Buy |
| 2016-03-02 | 繰り返されました | Needham | Buy |
| 2016-02-29 | 繰り返されました | Wedbush | Outperform |
| 2015-11-11 | 繰り返されました | Needham | Buy |
| 2015-08-18 | 繰り返されました | WBB Securities | Strong Buy |
| 2015-08-10 | 開始されました | ROTH Capital | Buy |
すべてを表示
Omeros Corporation (OMER) 最新ニュース
Wall Street Zen Upgrades Omeros (NASDAQ:OMER) to Hold - MarketBeat
Omeros (NASDAQ:OMER) Trading Down 5.1%Here's What Happened - MarketBeat
Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder - MSN
Omeros Corporation (OMER): Novo Nordisk Deal Creating Buzz - Insider Monkey
Omeros Corporation's (NASDAQ:OMER) Shift From Loss To Profit - Yahoo Finance
Do You Believe Omeros Corporation’s (OMER) New Monoclonal Antibody Has Strong Chances of Approval? - Insider Monkey
Omeros Corporation (NASDAQ:OMER) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Omeros Completes Major Asset Deal with Novo Nordisk - MSN
Is Omeros Corporation (OMER) One of the Hot Stocks to Buy with Huge Upside Potential? - MSN
Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call - MSN
Omeros (NASDAQ:OMER) Stock Price Up 8.2%Still a Buy? - MarketBeat
Can Omeros Corporation stock outperform in 2025 bull marketJuly 2025 Update & Short-Term High Return Ideas - Newser
11 Best Micro-Cap Stocks to Invest in According to Analysts - Insider Monkey
Omeros (NASDAQ:OMER) Given Buy Rating at D. Boral Capital - MarketBeat
Aug Sentiment: Is Omeros Corporation stock attractive for income investorsMarket Volume Report & Smart Allocation Stock Tips - moha.gov.vn
How Omeros Corporation stock performs in weak economyChart Signals & Entry Point Confirmation Alerts - Newser
Omeros (OMER) Receives Consistent 'Buy' Rating from D. Boral Cap - GuruFocus
Omeros Shares Jump After Finalizing $340 Million Novo Nordisk Deal - MSN
Omeros, Novo Nordisk close up to $2.1B deal for phase 2 asset zaltenibart - MSN
Omeros (OMER) Secures $2.1B Deal with Novo Nordisk - GuruFocus
Omeros Closes Asset Purchase, Licensing Deal With Novo Nordisk for Zaltenibart - MarketScreener
Omeros, Novo Nordisk Close Up to $2.1B Deal for Rare Disease Drug Zaltenibart, NOVO Stock - Somos Hermanos -
Omeros receives $240 million upfront from Novo Nordisk deal By Investing.com - Investing.com Canada
Omeros receives $240 million upfront from Novo Nordisk deal - Investing.com
Omeros stock surges after closing $340 million deal with Novo Nordisk - Investing.com Australia
Omeros stock surges after closing $340 million deal with Novo Nordisk By Investing.com - Investing.com South Africa
Omeros closes asset purchase and license deal with Novo Nordisk for MASP-3 inhibitor zaltenibart - marketscreener.com
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) - Yahoo Finance
Omeros Corporation (NASDAQ:OMER): When Will It Breakeven? - simplywall.st
What catalysts could drive Omeros Corporation stock higher2025 Short Interest & Weekly Top Stock Performers List - moha.gov.vn
Omeros jumps as lead drug succeeds in pivotal trial for blood transplant patients - MSN
Omeros (NASDAQ:OMER) Shares Pass Above 200 Day Moving AverageHere's Why - MarketBeat
Omeros: Key Milestone Ahead, Risk-Averse Investors Should Avoid (NASDAQ:OMER) - Seeking Alpha
What technical signals suggest for Omeros Corporation stockMarket Performance Recap & Real-Time Volume Trigger Notifications - newser.com
Omeros Corporation Stock Analysis and ForecastInsider Selling Patterns & Free Stock Trading Workshops - earlytimes.in
Is Omeros Corporation stock cheap compared to fundamentalsIPO Watch & Technical Entry and Exit Tips - newser.com
Omeros gets FDA acceptance for narsoplimab BLA resubmission - MSN
Omeros (NASDAQ:OMER) Shares Down 5.6%Should You Sell? - MarketBeat
Here's Why Shares in Theravance Biopharma Exploded Today - AOL.com
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal - AOL.com
How strong is Omeros Corporation stock revenue growthBuy Signal & Fast Exit/Entry Strategy Plans - newser.com
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why - AOL.com
Omeros (NASDAQ:OMER) Stock Price Up 8.1%Time to Buy? - MarketBeat
Omeros Corporation (NASDAQ:OMER) Q3 2025 Earnings Call Transcript - Insider Monkey
Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying - AOL.com
Omeros Corporation (OMER) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):